Celltrion acquires Swiss firm iQone Healthcare

15 November 2024

South Korean biosimilars company Celltrion (Kosdaq: 068270) today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland.

The acquisition, expected to close by the end of 2024, represents a significant milestone in Celltrion’s European expansion strategy. Upon completion, iQone Healthcare - which has acted as Celltrion’s distributor for a number of years, will become a wholly-owned subsidiary of Celltrion Healthcare Hungary Kft. The deal will also provide Celltrion with access to in-licensing opportunities, further strengthening its pipeline of innovative therapies.

The acquisition, valued at approximately 30 billion won ($21 million), is expected to enhance operational efficiency and marketing synergies.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK